MX2007003272A - Tratamiento de la osteoporosis inducida por medio de la falta de androgenos. - Google Patents

Tratamiento de la osteoporosis inducida por medio de la falta de androgenos.

Info

Publication number
MX2007003272A
MX2007003272A MX2007003272A MX2007003272A MX2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A
Authority
MX
Mexico
Prior art keywords
androgen
induced osteoporosis
deprivation induced
treatment
incidence
Prior art date
Application number
MX2007003272A
Other languages
English (en)
Spanish (es)
Inventor
Mitchell S Steiner
Karen A Veverka
Sharan Raghow
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of MX2007003272A publication Critical patent/MX2007003272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2007003272A 2004-09-20 2005-09-19 Tratamiento de la osteoporosis inducida por medio de la falta de androgenos. MX2007003272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/944,465 US20050080143A1 (en) 2001-11-29 2004-09-20 Treatment of androgen-deprivation induced osteoporosis
PCT/US2005/032998 WO2006033979A1 (en) 2004-09-20 2005-09-19 Treatment of androgen - deprivation induced osteoporosis

Publications (1)

Publication Number Publication Date
MX2007003272A true MX2007003272A (es) 2007-06-05

Family

ID=36090335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003272A MX2007003272A (es) 2004-09-20 2005-09-19 Tratamiento de la osteoporosis inducida por medio de la falta de androgenos.

Country Status (12)

Country Link
US (1) US20050080143A1 (https=)
EP (2) EP1935415A3 (https=)
JP (2) JP2008513469A (https=)
KR (1) KR20070059167A (https=)
CN (2) CN101961327A (https=)
AU (1) AU2005287113B2 (https=)
BR (1) BRPI0515668A (https=)
CA (1) CA2581159A1 (https=)
EA (1) EA014309B1 (https=)
IL (1) IL182091A0 (https=)
MX (1) MX2007003272A (https=)
WO (1) WO2006033979A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
CN116869944A (zh) * 2023-08-15 2023-10-13 重庆士立德医药科技有限公司 一种托瑞米芬组合物及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB8508404D0 (en) * 1985-03-30 1985-05-09 Baylor College Medicine Therapeutic compositions
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
FR2578113B1 (fr) * 1985-02-25 1988-04-15 Merlin Gerin Declencheur statique numerique a fonctions optionnelles pour un disjoncteur electrique
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
HUT60139A (en) * 1989-07-07 1992-08-28 Endorecherche Inc Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
US5153622A (en) * 1989-08-03 1992-10-06 Asahi Kogaku Kogyo Kabushiki Kaisha Pressure alarm for water-sealed camera
JPH06287885A (ja) * 1991-04-15 1994-10-11 Yamauchi Corp 脱水プレス用エンドレスベルト
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
TW303299B (https=) * 1993-07-22 1997-04-21 Lilly Co Eli
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
WO1997035000A1 (en) * 1996-03-18 1997-09-25 The Trustees Of The University Of Pennsylvania Bioactive material substrate for enhanced cellular attachment and function
GB9712086D0 (en) * 1997-06-10 1997-08-13 Bp Chem Int Ltd Process for preparing polyketones
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
SI1003496T1 (en) * 1998-05-07 2005-10-31 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413535B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
CN1400904A (zh) * 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP2003534375A (ja) * 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
BR0111298A (pt) * 2000-06-28 2005-05-10 Bristol Myers Squibb Co Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
EP1324754A1 (en) * 2000-07-05 2003-07-09 AstraZeneca AB Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
ATE288303T1 (de) * 2000-11-30 2005-02-15 Pfizer Prod Inc Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
US6413633B1 (en) * 2001-04-18 2002-07-02 Francis Patrick McCullough Activated biregional fiber(s)
WO2002091993A2 (en) * 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
US20030017151A1 (en) * 2001-05-17 2003-01-23 Dougall William C. Therapeutic use of rank antagonists
MXPA04005112A (es) * 2001-11-29 2005-04-29 Gtx Inc Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno.
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040152733A1 (en) * 2002-03-15 2004-08-05 Wallace Owen Brendan Duloxetine for treatment of hot flashes
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
US6838684B2 (en) * 2002-08-23 2005-01-04 Asml Netherlands B.V. Lithographic projection apparatus and particle barrier for use therein
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
MXPA05011299A (es) * 2003-04-30 2006-01-24 Debiopharm Sa Metodos y composiciones utilizando la hormona liberadora de la hormona gonadotropina.
US7048210B2 (en) * 2003-05-21 2006-05-23 Frank Clark Showerhead with grooved water release ducts
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof

Also Published As

Publication number Publication date
AU2005287113B2 (en) 2011-06-16
EP1796643A4 (en) 2009-09-09
EP1796643A1 (en) 2007-06-20
BRPI0515668A (pt) 2008-07-29
EP1935415A2 (en) 2008-06-25
JP2009029823A (ja) 2009-02-12
EP1935415A3 (en) 2009-09-16
CN101056621A (zh) 2007-10-17
EA200700690A1 (ru) 2007-10-26
CA2581159A1 (en) 2006-03-30
CN101056621B (zh) 2010-11-10
JP2008513469A (ja) 2008-05-01
CN101961327A (zh) 2011-02-02
EA014309B1 (ru) 2010-10-29
IL182091A0 (en) 2011-08-01
US20050080143A1 (en) 2005-04-14
AU2005287113A1 (en) 2006-03-30
WO2006033979A1 (en) 2006-03-30
KR20070059167A (ko) 2007-06-11

Similar Documents

Publication Publication Date Title
WO2003047504A3 (en) Prevention and treatment of androgen-deprivation induced osteoporosis
EP1816996A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
AU2003253877A1 (en) Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
TW200515910A (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
IL175568A (en) Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
EP1628667A4 (en) METHOD FOR TREATING DISEASES USING HSP90 INHIBITION AGENTS COMBINED WITH ANTIMITOTICS
WO2005000212A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
MX335951B (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
MX2007003272A (es) Tratamiento de la osteoporosis inducida por medio de la falta de androgenos.
EP1581095A4 (en) THERAPEUTIC METHODS FOR REDUCING FAT DEPOSIT AND TREATING THE DISEASES THEREOF
MX382930B (es) Tratamiento con cis-clomifeno de sofocos y pérdida ósea inducidos por privación de andrógeno terapéutica.
EP1753425A4 (en) THERAPEUTIC AGENT COMPRISING A NICOTINIC ACID OR DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
WO2011094260A3 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
IL166062A0 (en) Compositions and methods for therapeutic treatment
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
WO2008106606A3 (en) Carotenoid analogs and derivatives in the treatment of prostate cancer